Media & Resources

New Prevention Tools Still Needed Urgently In advance of the XVII International AIDS Conference in Mexico City, the Joint United Nations Programme on HIV/AIDS (UNAIDS) released their 2008 Report on the global AIDS epidemic, which indicated, among other things, that new HIV infections and AIDS-related deaths have declined in recent years. According to the new…

As a member of Global Health Technologies Coalition, IAVI applauds the historic bipartisan effort, as well as the bold leadership, of both the Congress and Administration in ensuring that the critical Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis and Malaria Reauthorization Act of 2008 was passed. This important legislation…

NEW YORK, July 17, 2008 —Today, the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) announced that it will not go ahead with the proposed Phase IIb AIDS vaccine trial known as PAVE 100.  The announcement followed the failure last September of an AIDS vaccine candidate with some similarities to…

NEW YORK, July 3, 2008—Dr. Thomas Hassell, former global vice president of process development at sanofi pasteur, the largest vaccine company worldwide, has joined IAVI as vice president for vaccine development. In his new role, Dr. Hassell will lead IAVI’s product development efforts that are aimed at rapidly advancing promising vaccine candidates that emerge from…

The International AIDS Vaccine Initiative (IAVI) has named Lipoxen, PLC, a leading UK-based biopharmaceutical company, and Strand Life Sciences, a premier life sciences company based in Bangalore, India, as the latest award recipients of the organization’s Innovation Fund—a new seed capital fund designed to bring novel, early-stage technologies to the field of AIDS vaccine research.…

Debunking the Myth 25 Years Later:  An AIDS Vaccine is Possible and Still Urgently Needed  NEW YORK, NY, May 16, 2008 —Twenty-five years since the discovery of HIV, the world has made considerable advances in addressing the AIDS pandemic. Scientists have learned a tremendous amount about HIV, perhaps more than any other pathogen, and have…

National Community Fund and Greystone Capital CDE Provide Tax Credit Financing for Construction of AIDS Vaccine Development Lab at New York’s Brooklyn Army Terminal  NEW YORK, April 25, 2008– National Community Fund I, LLC (NCF) and Greystone CDE, LLC (Greystone), closed New Markets Tax Credit (NMTC) financing for a new AIDS Vaccine Development Laboratory for…

Leading HIV Researchers to Collaborate on Vaccine Development DURHAM, NC, and NEW YORK, NY – Two global research organizations dedicated to designing a vaccine against HIV – the International AIDS Vaccine Initiative (IAVI), and the Center for HIV/AIDS Vaccine Immunology (CHAVI) – have signed an agreement to work together to address major biological questions that…